直击阿尔兹海默致病基因，微芯生物公布全球首个ApoE4小分子药物

Core Viewpoint - Shenzhen Micron Biotechnology Co., Ltd. held the 2025 Innovation Seminar in Shanghai, focusing on the application of "AI-assisted design + chemical genomics integrated technology platform" in new drug development, showcasing a new generation of First-in-Class early drug development pipeline [1] Group 1: Company Developments - The seminar highlighted the global first small molecule drug development project targeting the ApoE4 target, named CDCS04 [1] - Micron Biotechnology reported the discovery of a series of ApoE4 active candidate molecules based on the AI-assisted design and chemical genomics integrated technology platform [1] Group 2: Clinical Research Insights - The identified candidate molecules exhibit high blood-brain barrier permeability and good in vivo safety, showing protective effects on ApoE4 cell neuronal axon growth in preclinical studies [1] - The candidate molecules significantly reduced the phosphorylation levels of Tau protein in the cortex and hippocampus of ApoE4TR mice [1] Group 3: Disease Relevance - ApoE4 is recognized as the strongest genetic risk factor for Alzheimer's disease, with one ApoE4 allele increasing the risk of late-onset Alzheimer's disease by 3-4 times, and two alleles increasing the risk by 9-15 times, potentially leading to earlier onset of the disease [1]